Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 4/20 | 0.47 |
| ▸ | CA4 | P22748 | 4/20 | 0.47 |
| ▸ | CA9 | Q16790 | 4/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4933217 | 0.85 | MAPT (0.46) | CA1CA2CA4CA9ALDH1A1 | |
| SCHEMBL4934485 | 0.82 | SLC6A2 (0.47) | CA1CA2CA4CA9SLC6A2 | |
| SCHEMBL6926417 | 0.82 | SLC6A2 (0.65) | CA1CA2CA4CA9SLC6A2 | |
| SCHEMBL10413244 | 0.82 | SLC6A2 (0.65) | CA1CA2CA4CA9SLC6A2 | |
| SCHEMBL22285003 | 0.82 | SLC6A2 (0.65) | CA1CA2CA4CA9SLC6A2 | |
| SCHEMBL28475644 | 0.80 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3TDP1L3MBTL1 | |
| SCHEMBL8238773 | 0.78 | PARP1 (0.54) | CA1CA2CA4CA9SLC6A2 | |
| SCHEMBL12520753 | 0.77 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3HRH3 | |
| SCHEMBL15557524 | 0.76 | DAO (0.46) | CA1CA2CA4CA9SLC6A2 | |
| SCHEMBL18600519 | 0.76 | SLC6A4 (0.54) | CA1CA2CA4CA9SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117126153-A | New coronavirus inhibitor, preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2023-11-28 | — | — | CN | disclosed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
| EP-1940785-A2 | ACYCLIC 1,4-DIAMINES AND USES THEREOF | SmithKline Beecham Corporation (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007030761-A2 | ACYCLIC 1,4-DIAMINES AND USES THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
| US-7189729-B2 | Methods and compositions as protein kinase inhibitors | IRM LLC (BM) | 2007-03-13 | — | — | US | disclosed |
| US-20070010529-A1 | Nitrogenous heterocyclic compounds and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1670771-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2006-06-21 | — | — | EP | disclosed |
| US-20050171105-A1 | For therapy of benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC (BM) | 2005-08-04 | — | — | US | disclosed |
| WO-2005033086-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171105-A1 | For therapy of benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | ERBB2, ERBB3, ERBB4 | CA1 4607/4885CA2 2608/4885CA4 3078/4885 |
| US-20070010529-A1 | Nitrogenous heterocyclic compounds and medical use thereof | MAPK1, NOS1, NOS2 | CA1 1486/4885CA2 1212/4885CA4 2114/4885 |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | CA1 1033/4885CA2 182/4885CA4 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.